High flow nasal oxygen for prevention of intubation in acute non-hypercapnic hypoxemic respiratory failure in immunocompromised patients, a randomized trial
Phase 4
Recruiting
- Conditions
- Acute hypoxemic respiratory failure due to pneumonia in immunocompromised patients
- Registration Number
- TCTR20171106003
- Lead Sponsor
- Faculty of medicine, Chiang Mai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
all the following
1.Immunocompromised patients: solid or hematologic malignancy, received immunosuppressive drug or steroid at a dose> 20 mg/day of prednisolone for > 30 days, HIV infection
2.Require nasal low-flow oxygen of 4 L/min to maintain PaO2 above 60 mmHg or SpO2> 90% for > 1 hour
3.Age >= 18 years
Exclusion Criteria
Exclusion
1.PaCO2> 45 mmHg
2.Post-extubation respiratory failure (respiratory failure within 48 hr after extubation)
3.Life-threatening ARF requiring immediate IMV
4.Shock
5.Active pulmonary tuberculosis
6.Contraindications to NIV
7.A do-not-intubate order
8.Patients refused to participate the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Required intubation and IMV within 48 hours of randomization within 48 hours of randomization rate of intubation
- Secondary Outcome Measures
Name Time Method Mortality 30-day mortality rate